People with advanced head and neck cancer can live longer on immunotherapy compared with standard treatment, a major trial has found.
Immunotherapy is proving life-saving for some patients with different types of the cancer. It works by convincing the person’s own immune system to recognise and attack cancer cells.
Now, a major trial has backed the therapy as a first-line treatment for people with advanced head and neck cancer.
Professor Paul Workman
About 12,000 people are newly-diagnosed each year in the UK, half of them at an advanced stage, and it kills about 4,000 people annually.
The trial was led by the Institute of Cancer Research in London.
Professor Paul Workman, its chief executive, said: “We have seen a series of innovative new cancer treatments over the last few years.
“The next big challenge is to get them to patients as early as possible in the treatment pathway, as this new research does.”
Enjoy the convenience of having The Sunday Post delivered as a digital ePaper straight to your smartphone, tablet or computer.
Subscribe for only £5.49 a month and enjoy all the benefits of the printed paper as a digital replica.
